bintrafusp alfa + carboplatin + pemetrexed

Bintrafusp alfa + carboplatin + pemetrexed is an investigational combination regimen for cancer therapy, typically studied in the context of non-small cell lung cancer (NSCLC) and potentially other solid tumors. - **Bintrafusp alfa** is a first-in-class bifunctional fusion protein designed to simultaneously block programmed death-ligand 1 (PD-L1) and sequester transforming growth factor beta (TGF-β) within the tumor microenvironment. It is composed of the extracellular domain of TGF-β receptor II fused to a human IgG1 antibody targeting PD-L1. By inhibiting both immune checkpoint and TGF-β mediated immunosuppression, bintrafusp alfa enhances antitumor immune responses, promotes CD8+ T cell and NK cell activation, reverses epithelial-mesenchymal transition (EMT), and improves chemotherapy sensitivity[1][2]. - **Carboplatin** is a platinum-based chemotherapeutic agent that causes DNA crosslinking and cell death, primarily by disrupting DNA replication (small molecule, cytotoxic)[2]. - **Pemetrexed** is an an antimetabolite cytotoxic drug that inhibits several folate-dependent enzymes essential for DNA synthesis and function (small molecule, cytotoxic)[2]. This combination is under clinical investigation, with no approved brand name as a combined product.